In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
Can multifaceted strategies improve hypertension control in low-income patients?
Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood pressure control continues to be a major challenge, especially in low-income populations. The IMPACTS-BP trial has arrived, a study evaluating whether a multifaceted team-based strategy can improve blood pressure control and adherence to antihypertensive therapy.
Check out the VA by Dra Akshaya Jayachandran, and don’t forget to join the live discussion with @NephJC on X and Bluesky
¿Puede el trabajo colaborativo mejorar el control de la hipertensión?
La hipertensión arterial continúa siendo uno de los principales factores de riesgo cardiovascular a nivel mundial. Sin embargo, lograr un adecuado control de la presión arterial sigue siendo un desafío, especialmente en poblaciones de bajos ingresos. Hoy aterriza el ensayo IMPACTS-BP, un estudio que evaluó si una estrategia multifacética basada en equipos puede mejorar el control y la adherencia al tratamiento antihipertensivo.
Revisa el resumen visual realizado por la Dra Akshaya Jayachandran y no olvides unirte en vivo con @NephJC en X y Bluesky
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones? POTCAST desafía nuestro miedo al potasio.
Revisa el resumen visual por Jeyakumar Meyyappan y únete a la conversación en #NephJC
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.
1/10 Last #NephJC we discussed pegcetacoplan in C3 glomerulopathy and Immune-Complex MPGN #TenPostNephJC
— Nephrology Journal Club (@NephJC) January 16, 2026
Given the central role of complement dysregulation in C3GN, the 🔑 question was whether 🎯 complement inhibition could deliver clinical benefithttps://t.co/1GyC3P8emi pic.twitter.com/Hllq7tEJaG
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
— Nephrology Journal Club (@NephJC) November 24, 2025
Read the @NEJM article 👇 https://t.co/yBMbZtb7XG pic.twitter.com/6vp0tROznZ
Stunning visual abstract summarizing NEJM study, by Priti Meena
How low is too low for blood pressure? Will BPROAD get to the bottom of this issue?
Microvascular inflammation from the perspective of a real unicorn: donor-specific antibodies with negative antibody mediated rejection 🦄
